[Comment] Offline: President Trump—It Is Not Too Late

Why It Matters

The funding retreat jeopardizes global HIV control, wastes U.S. research investments and creates a national‑security risk by fostering a resurgence of infections in a region critical to worldwide health security.

Key Takeaways

• US cuts slashed primary HIV testing and prevention in South Africa
• Antiretroviral and PrEP supplies disrupted, increasing infection risk
• Research staff dismissed, halting clinical trials and vaccine development
• Funding gap forces reliance on WHO, Global Fund, and other donors
• PHR warns cuts waste American investment and pose national security risk

Pulse Analysis

For decades the United States has been the backbone of global HIV/AIDS financing, channeling billions through USAID, NIH and CDC into testing, treatment and groundbreaking research. The Trump administration’s recent budget reductions reversed that trajectory, slashing the roughly $1.2 billion annual contribution that accounted for 17 % of South Africa’s HIV response. This abrupt withdrawal not only curtails life‑saving antiretroviral distribution but also erodes the surveillance infrastructure that tracks new infections and viral suppression, undermining decades of progress.

The Physicians for Human Rights report paints a stark picture: clinics that once offered free testing and counseling are now understaffed, PrEP injectables like lenacapavir are scarce, and pivotal clinical‑trial personnel have been laid off. In South Africa, the world’s largest HIV epidemic, these gaps translate into thousands of preventable infections and a surge in mortality. Kenya’s rollout of long‑acting PrEP is similarly stalled, illustrating how funding cuts ripple across the continent. The loss of U.S.‑sponsored research capacity also threatens future innovations, as South Africa’s laboratories have been a proving ground for therapies that benefit both African and American patients.

Policymakers face a clear choice. Restoring U.S. contributions, or at least maintaining a baseline, would re‑enable testing, treatment continuity and data collection essential for epidemic control. Meanwhile, multilateral bodies such as the Global Fund and WHO must step up financing and hold the U.S. accountable, while other donor nations and private foundations can fill immediate gaps. The stakes extend beyond public health; unchecked HIV spread can destabilize economies and strain health systems, representing a broader national‑security concern for the United States.